SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 19, 2017
NuLife Sciences, Inc.
(Exact Name of Registrant as Specified in Charter)
|(State of Other Jurisdiction
2618 San Miguel, Suite 203
Newport Beach, CA
|(Address of Principal Executive Offices)
Registrant’s telephone number, including
area code: (949) 973-0684
(Former Name or Former Address, if Changed Since
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On December 19, 2017, John Hollister resigned
as Chief Executive Officer of NuLife Sciences, Inc. (the “Company”). Mr. Hollister was appointed as Chief Executive
Officer of the Company on May 15, 2017.
Item 8.01 Other Events.
On December 19, 2017, the Company terminated
that certain non-binding Letter of Intent between the Company and Ensysce Biosciences, Inc.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
||NuLife Sciences, Inc.|
|Date: December 26, 2017
||By: /s/ Fred Luke|
|| Fred Luke, President|